Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Concord Biotech Limited

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.

The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

Rising Tide

Quadria Capital

Neuberger Berman

Critically ill patients on ventilators face a high risk of lower respiratory tract infections, such as ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). VAP is linked to increased morbidity and mortality in the ICU, emphasizing the need for prevention. 

This review examines the potential of pre-emptive aerosolized antibiotics (AA) in preventing ventilator-associated infections and whether aerosolized treatment for VAT can halt its progression to VAP. 

Read more: https://lnkd.in/dX6msByM 

#respiratoryinfections #ventilatorassociatedpneumonia #aerosolizedantibiotics #ventilatorassociatedtracheobronchitis #criticalcare #intensivecare

Concord Biotech stands united on World AIDS Day, spreading awareness and knowledge to foster a world free from HIV/AIDS. Together, let's strive for prevention, support, and a brighter, healthier future for all.

#WorldAIDSDAY2023
#WorldAIDSDay  #HIV #AIDS #HIVawareness #AIDSawareness

Tune in to today's episode of Good Health Conquest as we discuss the Role of the granzyme family in rheumatoid arthritis. Our spotlight turns to the granzyme family, specifically granzymes A, B, M, K, and the enigmatic granzyme H, shedding light on their potential role in rheumatoid arthritis pathogenesis.

Listen now: https://lnkd.in/d5UCpmhA
For more information, visit www.conquest.health

#RA #Rheumatoidarthritis #Granzyme #pathogenesis #podcast #Concordbiotech #GoodHealthConquest

On this Gurupurab, may the teachings of Guru Nanak Dev Ji inspire you to lead a life of compassion and righteousness. Happy Gurupurab!

#HappyGurupurab #Gurupurab #GuruNanakJayanti #HappyGuruNanakJayanti #ConcordBiotech

On today's episode of the Good Health Conquest, we discuss the Current Therapies in Kidney Transplant Rejection, specifically acute T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR). Stay tuned as we navigate the evolving landscape of kidney transplantation, striving for improved long-term outcomes and a deeper understanding of rejection mechanisms.

Listen now: https://lnkd.in/dU-xVv2q Find us on all major listening platforms and apps. For more information, visit our website at www.conquest.health

#kidneytransplant #renaltransplant #treansplantrejection #rejection #posttransplant #kidneycomplications #Concordbiotech

While there are chances to enhance antibiotic prescribing throughout the care spectrum, the discharge phase from hospitalization is a notable contributor to antibiotic overuse. 

Thus, it becomes imperative to improve antibiotic prescribing by optimizing antibiotic selection, reassessing antibiotic treatment, and using the shortest effective duration of therapy post-discharge.  

#Antibioticresistance #AntimicrobialAwarenessWeek #AntimicrobialResistance #WorldAntimicrobialAwarenessWeek #WAAW #WAAW2023 #AMR

	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue	1.81B -	1.59B 12.21%	2.41B 51.47%	2.50B 3.89%	1.95B 22.08%	2.62B 34.66%	2.41B 8.21%	3.19B 32.46%	2.16B 32.34%	3.10B 43.73%
cost of revenue	391.84M -	349.51M 10.80%	494.41M 41.46%	734.91M 48.64%	816.94M 11.16%	528.68M 35.28%	470.87M 10.94%	1.37B 189.93%	931.41M 31.77%	763.18M 18.06%
gross profit	1.42B -	1.24B 12.60%	1.91B 54.29%	1.77B 7.68%	1.13B 35.92%	2.09B 85.16%	1.94B 7.53%	1.82B 5.81%	1.23B 32.77%	2.34B 90.66%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	251.68M -				540.23M -	601.23M 11.29%	571.09M 5.01%	618.82M 8.36%
research and development expenses
other expenses		60.29M -	92.50M 53.42%	-169.05M 282.77%		81.27M -	81.87M 0.75%	108.12M 32.05%	-545.60M 604.64%	2.34B 528.63%
cost and expenses	1.16B -	1.33B 15.13%	1.43B 6.95%	1.20B 16.17%	1.36B 13.40%	1.56B 15.28%	1.48B 5.14%	1.98B 33.69%	1.48B 25.55%	3.10B 110.01%
operating expenses	767.66M -	985.41M 28.37%	933.33M 5.29%	461.91M 50.51%	540.23M 16.95%	1.04B 91.74%	1.01B 2.19%	618.82M 38.92%	545.60M 11.83%	2.34B 328.63%
interest expense		11.10M -	9.09M 18.12%	14.55M 60.07%	7.53M 48.22%	8.41M 11.60%	4.95M 41.08%	4.63M 6.56%	2.41M 47.97%	956K 60.30%
ebitda	632.62M -	434.70M 31.29%	1.19B 174.26%	1.39B 16.80%	721.52M 48.18%	1.24B 71.64%	1.17B 5.41%	1.34B 14.64%	812.79M 39.47%	1.44B 76.85%
operating income	510.63M -	309.59M 39.37%	1.05B 240.62%	1.25B 18.60%	591.11M 52.73%	1.06B 79.14%	923.92M 12.75%	1.21B 30.50%	681.00M 43.52%
depreciation and amortization	122.00M -	125.11M 2.55%	137.70M 10.06%	141.85M 3.02%	130.41M 8.06%	132.95M 1.95%	135.37M 1.82%	137.18M 1.34%	131.78M 3.93%	133.14M 1.03%
total other income expenses net	129.51M -	-11.10M 108.57%	-9.09M 18.12%	-14.55M 60.07%	59.01M 505.67%	72.86M 23.46%	76.92M 5.58%	103.49M 34.54%	100.67M 2.72%	1.30B 1,194.69%
income before tax	640.14M -	298.49M 53.37%	1.05B 250.24%	1.24B 18.24%	650.12M 47.40%	1.10B 68.74%	1.03B 6.02%	1.31B 26.98%	781.67M 40.29%	1.30B 66.74%
income tax expense	147.55M -	78.82M 46.58%	271.74M 244.77%	321.17M 18.19%	165.42M 48.49%	286.85M 73.41%	255.31M 11.00%	337.04M 32.01%	199.28M 40.87%	345.94M 73.59%
net income	492.58M -	219.67M 55.40%	773.68M 252.20%	914.90M 18.25%	544.94M 40.44%	810.20M 48.68%	775.73M 4.25%	950.16M 22.49%	595.93M 37.28%	957.41M 60.66%
weighted average shs out	104.58M -	104.62M 0.03%	104.62M 0%		104.62M -	104.62M 0%	104.62M 0%	104.62M 0%	104.62M 0%	104.63M 0.02%
weighted average shs out dil	104.58M -	104.62M 0.03%	104.62M 0%		104.62M -	104.68M 0.06%	104.69M 0.01%	104.62M 0.07%	104.62M 0%	104.63M 0.02%
eps	4.71 -	2.10 55.41%	7.40 252.38%	0 100%	5.21 Infinity%	7.74 48.56%	7.41 4.26%	9.08 22.54%	5.70 37.22%	9.15 60.53%
epsdiluted	4.71 -	2.10 55.41%	7.40 252.38%	0 100%	5.21 Infinity%	7.74 48.56%	7.41 4.26%	9.08 22.54%	5.70 37.22%	9.15 60.53%

CONC

COM:CONCORDBIOTECH

Concord Biotech

Last Close

2,031.55

25/11 09:20

Market Cap

176.73B

Beta: -

Volume Today

7.43K

Avg: -

Preview